The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients

Suzuki, K.; Kato, Kiminori; Soda, Satoshi; Kamimura, Takashi; Aizawa, Yoshifusa

doi:10.1111/j.1462-8902.2004.00331.x

Cited by 6 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Beneficial effects of valsartan were reported by Thürmann et al in 58 patients, 28 by Mutlu et al in 30 patients 29 , by Gottdiener et al , 30 and by Suzuki et al (in type 2 diabetics) 31 . Picca et al in 2004 reported a head-to-head comparison of valsartan 160 mg with losartan 100 mg in a small cohort of patients ( n = 30) with untreated hypertension and concentric LVH.…”

Section: Discussionmentioning

confidence: 86%

Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension

Bruder

Jensen

Bell

et al. 2011

Journal of Drug Assessment

View full text Add to dashboard Cite

BackgroundLeft ventricular hypertrophy (LVH), a marker of cardiac end-organ damage, is frequently found in patients with arterial hypertension and is associated with cardiovascular and cerebrovascular morbidity and mortality. Therefore, LVH regression is an important treatment goal. For amlodipine plus valsartan (A/V) no specific study on LVH has been reported to date.MethodsProspective, open-label, randomized parallel-group study. Patients with essential hypertension and LVH were randomized to 52-week treatment with A/V 10/160 mg (n = 43) or the active comparator losartan/HCT 100/25 mg (L/H, n = 47). Add-on medication was allowed in case of inadequate blood pressure control. LV parameters were measured by cardiovascular magnetic resonance imaging (MRI), and adjudicated in a blinded manner. Study identifiers were NCT00446563 and EudraCT 2006-001977-17.ResultsIn addition to the study treatment, 35% of patients in the A/V group and 49% in the L/H group received additional antihypertensive medication. Compared to baseline, both treatments reduced measures of LVH significantly after 52 weeks (e.g. LV mass index in the A/V group from 64.7 g/m2 by −3.5 g/m2, in the L/H group from 69.1 g/m2 by −4.4 g/m2, p < 0.01 for both). LV ejection fraction and LV volumes were not significantly changed by any regimen. A/V and L/H treatments were well tolerated.ConclusionsBoth regimen were effective in reducing LV mass compared to baseline and were well tolerated.

show abstract

Section: Discussionmentioning

confidence: 86%

Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension

Bruder

Jensen

Bell

et al. 2011

Journal of Drug Assessment

View full text Add to dashboard Cite

show abstract

“…In an open-label study of 14 type 2 diabetics with LVH, lowdose valsartan (40 mg) significantly reduced LVH after 6 months (with further reductions after 12 months) without any effect on BP [33]or glycosylated hemoglobin This suggests that some other factor, presumably direct antagonism of the trophic effects of angiotensin II, was the causal mechanism.…”

Section: Angiotensin II Receptor Blockade In Treatment and Preventionmentioning

confidence: 88%

Regressing Left Ventricular Hypertrophy: The Role of Telmisartan and Other ARBs

Galzerano¹,

Tammaro

Lama³

et al. 2006

CHYR

View full text Add to dashboard Cite

Left ventricular hypertrophy (LVH) is a common form of target organ damage associated with hypertension that increases the risk for cardiovascular morbidity and mortality. Regression of left ventricular mass (LVM) substantially reduces this risk, and antihypertensive treatment is associated with reduction in LVM. Identifying the optimal therapeutic strategy that brings effective BP reductions and superior LVM regression is therefore important for the effective management of patients with LVH. Hypertension, both mean load and variability (for example, the early morning blood pressure [BP] surge), causes LVH. LVH also results from abnormalities in neurohormonal systems (such as the renin-angiotensinaldosterone system [RAAS]), and metabolic abnormalities. Agents that block the RAAS (angiotensin receptor blockers [ARBs], angiotensin-converting enzyme inhibitors) have particular efficacy. Telmisartan is a long-acting ARB that has shown regression of LVH and improved diastolic function in several clinical trials. Compared with carvedilol, telmisartan induces more regression of LVM for the same degree of BP control, and compared with hydrochlorothiazide the regression of LVM for a given degree of BP lowering is greater. As part of the ONTARGET study that compares telmisartan, ramipril, and the combination, a substudy will assess the effects of the three therapeutic strategies on the regression of LVH.

show abstract

“…Авторы пришли к выводу, что, помимо антигипертензивного эффекта, терапия валсартаном способствует регрессу ГЛЖ, улучшает сократимость миокарда и благоприятно влияет на процессы релаксации и диастолическую функцию ЛЖ. В другой работе [24] изучалось влияние терапией валсартаном в дозе 40 мг/сут на иММЛЖ у пациентов с сахарным диабетом 2 типа (n=38; возраст 57,7±2 лет; 14 человек из них исходно имели ГЛЖ), 57% из которых ранее принимали антигипертензивные препараты. Период наблюдения в исследовании равнялся 12 мес.…”

Section: статистическая обработка данныхunclassified

Effect of the Single-Pill Amlodipine/Valsartan Combination on Hypertrophy and Myocardial Deformation Characteristics in Middle-Aged Patients with Essential Arterial Hypertension

Кочетков

Борисова²,

Остроумова

et al. 2019

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Aim. To investigate the impact of amlodipine/valsartan single-pill combination (A/V SPC) on left ventricular hypertrophy (LVH) and left ventricular (LV) myocardial strain and stiffness parameters in naїve middle-aged patients with stage II grade 1-2 essential arterial hypertension (EAH).Material and methods. A group of patients with stage II grade 1-2 EAH who had not previously received regular antihypertensive treatment (AHT) [n=38; mean age 49.7±7.0 years] was retrospectively formed. All the patients were treated with A/V SPC and all of them achieved target office blood pressure (BP) (less than 140/90 mm Hg). And after 12 weeks follow-up (since the time of reaching the target BP) the AHT effectiveness assessment, its impact on LVH and LV myocardial strain and stiffness parameters (general clinical data, ambulatory blood pressure monitoring, conventional and 2D-speckle tracking echocardiography) were performed in all included patients.Results. The number of patients with LVH significantly (p=0.039) decreased from 25 individuals (65.8%) at baseline to 15 patients (39.5%) at the end of follow-up. Among patients with LVH at baseline after the treatment with A/V SPC significantly decreased (p<0.001 for all) interventricular septum thickness (from 1.36±0.19 to 1.28±0.18 cm), LV posterior wall thickness (from 1.08±0.09 to 0.97±0.11 cm) and the LV myocardial mass index (from 123.3±19.3 to 110.8±20.8 g/m2). At the end of follow-up end-systolic elastance significantly (p<0.001) decreased from 4.01±1.12 to 3.46±0.88 mm Hg/ml. In the subgroup of patients with reduced (in absolute value) LV longitudinal 2D-strain (n=27) at baseline, there was a significantly (p=0.005) increasing in this parameter at the end of the study (from -16.14±2.21% to -17.30±2.13%, Δ%=8.45±13.35).Conclusion. In naive patients 40-65 years old with stage II grade 1-2 EAH AHT with A/V SPC provides effective 24 hours BP control, significantly reduced LVH and improves LV strain parameters, which indicates decreasing of LV myocardial stiffness.

show abstract

The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients

Cited by 6 publications

References 27 publications

Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension

Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension

Regressing Left Ventricular Hypertrophy: The Role of Telmisartan and Other ARBs

Effect of the Single-Pill Amlodipine/Valsartan Combination on Hypertrophy and Myocardial Deformation Characteristics in Middle-Aged Patients with Essential Arterial Hypertension

Contact Info

Product

Resources

About